ATLANTA, January 6, 2020-- OncoLens, a pioneer in tumor board and cancer treatment planning software solutions, today announced it has raised a Pre-Series A funding of $2.5 million led by venture investment firm BIP Capital. Other investors in the round include Atlanta Technology Angels, and the Robbins Fund. All three were prior investors in the company’s seed round and are reaffirming their commitment to the business with this second funding round. According to the American Cancer Society, nearly 1.76 million new cancer cases were diagnosed in the United States in 2019, with 606,880 cancer deaths reported.